Recent Updates — GOVX

GeoVax Labs stockholders approved a proposal to effect a reverse stock split of its common stock at a ratio determined by the Board, ranging from 1-for-10 to 1-for-25. The vote passed with 3,484,374 shares in favor and 828,802 against. Separately, shareholders approved the issuance of up to 11,395,256 common shares upon exercise of warrants issued under a prior inducement program. GeoVax Labs is a biotechnology company focused on vaccine development.

GeoVax Labs entered into a $1,000,000 unsecured Revolving Loan Agreement with Bowery Consulting Group Inc. bearing 12% annual interest and maturing on the first anniversary of closing. The facility is subject to the Lender’s sole discretion for drawdowns and requires the Company to pursue a Qualified Public Equity Offering of at least $5,000,000. Concurrently, five directors resigned and three lender-designated nominees—Steven Brown, Tyler O’Brien, and Manpreet Uppal—were appointed to the Board, constituting a majority. GeoVax Labs is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer.

GeoVax Labs Inc. announced that its appeal hearing before the Nasdaq Hearings Panel regarding a delisting determination based on minimum bid price requirements is scheduled for October 13, 2026. The company received the initial delisting notice on August 27, 2026, but the pending appeal has stayed any suspension or delisting action, allowing common stock to continue trading under the symbol GOVX at least through that period. GeoVax intends to present a compliance plan to regain adherence to Nasdaq listing standards during the hearing. The company reaffirmed its strategic focus on advancing its priority program GEO-MVA toward a pivotal Phase 3 clinical trial and developing Gedeptin for oncology applications. GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies against high-consequence infectious diseases and solid tumor cancers.

GeoVax Labs, Inc. received a Nasdaq notice of non-compliance with the $2,500,000 minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). The company has until August 21, 2026, to submit a plan to regain compliance, with the potential for a 180-day extension if the plan is accepted. GeoVax Labs, Inc. is a biotechnology company focused on developing vaccine and immunotherapy products.